Adhesion properties of a putative polymorphic fimbrial subunit protein from *Bifidobacterium longum* subsp. *longum*

Kenta SUZUKI1#, Keita NISHIYAMA1, Hiroki MIYAJIMA1, Ro OSAWA3, Yuji YAMAMOTO1 and Takao MUKAI1*

1Department of Animal Science, School of Veterinary Medicine, Kitasato University, Towada, Aomori, Japan
2Department of Microbiology, School of Pharmacy, Kitasato University, Minato-ku, Tokyo, Japan
3Department of Bioresource Science, Graduate School of Agricultural Science, Kobe University, Kobe, Japan

Received July 17, 2015; Accepted August 27, 2015; Published online in J-STAGE September 26, 2015

In our previous study, we found that the open reading frame *bl0675* in the genome of *Bifidobacterium longum* subsp. *longum* isolated from human feces encoded a novel putative fimbrial protein, was highly polymorphic, and had five variants (A, B, C, D, and E types). The aim of this study was to evaluate the affinity of these variants to porcine colonic mucins (PCMs). Protein-binding properties were examined using the recombinant BL0675 protein containing a C-terminal 6 × His tag (His-BL0675). Surface plasmon resonance analysis demonstrated that the His-BL0675 A type had strong affinity to PCMs (\( K_D = 9.82 \times 10^{-8} \) M), whereas the B, C, D, and E types exhibited little or no binding. In a competitive enzyme-linked immunosorbent assay, His-BL0675 A type binding was reduced by addition of mucin oligosaccharides, suggesting that the binding occurs via carbohydrate chains of PCMs. The localization of BL0675 to the *B. longum* subsp. *longum* cell surface was confirmed by western blot analysis using A type polyclonal antibodies. Bacterial adhesion of *B. longum* subsp. *longum* to PCMs was also blocked by A type-specific antibodies; however, its adhesion properties were strain specific. Our results suggest that the BL0675 variants significantly contribute to the adhesion of *B. longum* subsp. *longum* strains. The expression and the adhesive properties of this protein are affected by genetic polymorphisms and are specific for *B. longum* subsp. *longum* strains. However, further studies are required on the properties of binding of these putative fimbrial proteins to the human gastrointestinal tract.

Key words: adhesion, *Bifidobacterium longum* subsp. *longum*, fimbrial subunit protein, mucin, surface plasmon resonance

**INTRODUCTION**

*Bifidobacterium* is one of the major genera of bacteria constituting the gastrointestinal (GI) microbiota in mammals, including humans [1]. The fecal microbiota of infants is characterized by high levels of bifidobacteria [2]. The abundance of bifidobacteria within the human gut decreases with age [3, 4]. Although the bifidobacteria in the adult colon comprise less than 10% of fecal microbes [5], their presence has been associated with beneficial health effects, such as boosting of immune defenses [6–9] and prevention of infection by pathogens [8, 10].

The mucus layer covering the GI tract is the first line of contact of the intestinal bacteria with the host and provides a habitat for the microbiota [11, 12]. Adhesion is an important prerequisite for the colonization of bacteria in the intestinal mucosa and provides a competitive advantage in this ecosystem [13]. Fimbriae and pili have been established as key structures involved in colonization of the GI tract by intestinal bacteria, not only in pathogens [14] but also in commensal bacteria, including several *Bifidobacterium* strains. For example, sortase-dependent pili from the *Bifidobacterium bifidum* PRL2010 strain have been shown to bind epithelial Caco-2 cells and the extracellular matrix (ECM) proteins fibronectin and laminin [15], while type IVb tight adherence (Tad) pili have been proven to be essential for *Bifidobacterium breve* UCC2003 colonization of the murine gut [16, 17].

*Bifidobacterium longum* subsp. *longum* is one of the
dominant bacterial species in the intestinal microbiota of adult humans [1, 18]. By sequencing the *B. longum* subsp. *longum* NCC2705 genome, Schell et al. [18] identified a cluster of three fimbria-associated open reading frames (ORFs) *bl0674*, *bl0675*, and *bl0676* possibly involved in fimbria formation. In a previous study performed using *B. longum* subsp. *longum* strains isolated from 89 human feces samples, we found that *bl0675* is highly polymorphic and encodes five variant types: A, B, C, D, and E [19]. Moreover, because the putative amino acid sequence of *bl0675* shows 30% homology to that of FimA, the major component of type 2 glycoprotein-binding fimbriae of *Actinomyces naeslundii* [20, 21], we hypothesized that the five *BL0675* variant types may have differing affinities to the carbohydrate chains in mucins. The aim of this study was to evaluate the binding affinity of the different types of *BL0675* to porcine colonic mucins (PCMs).

MATERIALS AND METHODS

Bacterial strains and growth conditions

*B. longum* subsp. *longum* isolates from human feces [19] were cultured in TOS propionate broth or agar (Yakult Pharmaceutical Industry Co., Ltd., Tokyo, Japan) supplemented with 0.05% (w/v) L-cysteine hydrochloride (Yakult Pharmaceutical Industry Co., Ltd., Tokyo, Japan) and 0.3% (w/v) L-ascorbic acid sodium salt (Wako, Tokyo, Japan) at 37°C under anaerobic conditions. *Escherichia coli* DH5α and Rosetta 2 (Stratagene, La Jolla, CA, USA) were grown in Luria-Bertani (LB) broth at 37°C. Ampicillin (100 µg/ml), kanamycin (30 µg/ml), or chloramphenicol (30 µg/ml) were added when necessary.

Cloning and DNA sequencing

The A and C types of *bl0675* were amplified by PCR with Ex Taq DNA polymerase (Takara Bio, Shiga, Japan) using genomic DNA of *B. longum* subsp. *longum* strains 4-10 and 10-121 as templates and primer sets KS039AF/KS039AR and KS042CR (Table 1). Purified amplicons were sequenced using primer KS039AF/KS039AC/KS040AR and KS042CR specific for the A and C types, respectively. Nucleotide sequences of the *bl0675* A and C types from *B. longum* subsp. *longum* strains 4-10, 1-124, 10-121, 7-8, and 2-124 as templates. The specific primer pairs used were KS013AF/KS014AR for the A type, KS016BF/KS017BR for the B type, KS018CF/KS019CR for the C type, KS023DF/KS024DR for the D type, and KS025EF/KS026ER for the E type (Table 1). The amplified fragments were inserted into the pGEM-T easy vector (Promega, Tokyo, Japan); the recombinant plasmids were then digested with the endonucleases *Nco*I and *BamHI* and the fragments were ligated into the pET28-b expression vector used to transform *E. coli* Rosetta 2. For recombinant protein expression, transformed bacteria were grown in LB medium at 30°C with shaking until the OD$_{600}$ reached 0.5 and then induced with isopropyl-β-D-thiogalactopyranoside (0.1 mM) at 30°C for 5 hr. Bacteria were harvested and resuspended in 3 ml lysis buffer (pH 7.0) containing 50 mM Tris-HCl, 1 mM EDTA, 1 mg lysozyme from chicken egg (Sigma-
Aldrich, St. Louis, MO, USA), and protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Crude lysates were fractionated by centrifugation (16,000 × g, 10 min, 4°C), and supernatants were filtered through a 0.20-μm filter. The samples were purified by Ni²⁺-nitrilotriacetic acid affinity chromatography using HisTrap HP columns (Qiagen, Hilden, Germany) and by ion exchange chromatography using SP-Sepharose Fast Flow (GE Healthcare, Piscataway, NJ, USA). Protein fractions were pooled and dialyzed against 10 mM HEPES buffer (pH 7.4). Protein purity was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 10% polyacrylamide gels, and protein concentration was determined using the BCA method (Thermo Scientific, Wilmington, DE, USA).

**Surface plasmon resonance (SPR) analysis**

The binding affinity of the His-BL0675 A type (His-BL0675A) to PCMs was assessed by SPR using a Biacore X instrument (GE Healthcare, Piscataway, NJ, USA) as previously described [22], with the following modifications. Purified PCMs were immobilized on a CM5 dextran sensor chip (GE Healthcare) with 2,706 resonance units (RUs) using amine-coupling reagents (GE Healthcare). The binding of His-BL0675A to the coated surface was determined on Biacore X using HBS-EP (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20; pH 7.4) at flow rate of 30 µl/min. The analyte His-BL0675A was diluted in HBS-EP buffer and injected over the chip, and dissociation was performed at the same flow rate for 2.5 min. For each binding assay, the specific binding signal was obtained after subtracting the signal of a blank surface. Sensor surface regeneration was achieved by 1-min exposure to regeneration buffer (50 mM Tris-HCl, 2 M NaCl, pH 9.5). The association rate (ka), dissociation rate (kd), and dissociation constant (K_D = kd/ka) were calculated using the BIAevaluation Software version 3.0 (GE Healthcare). Global analysis was performed using a simple 1:1 Langmuir binding model.

**Enzyme-linked immunosorbent assay (ELISA)**

ELISA was conducted as previously described [23] with some modifications. His-BL0675A was added to 96-well microtiter plates coated with PCMs and incubated at room temperature for 1 hr. After washing three times with HBS-EP buffer (pH 7.4), an anti-His-tag antibody (1:3,000; Roche) was added and the plates were incubated at room temperature for 40 min. After washing, alkaline phosphatase-conjugated anti-mouse IgG (1:4,500; Dako, Glostrup, Denmark) was added for 40 min at room temperature. Antibody-specific signals were detected with BluePhos MicroWell Substrate Kit (KPL, Gaithersburg, MD, USA) by measuring the absorbance at 620 nm.

**Competitive ELISA**

Competitive ELISA was performed to detect the interaction between His-BL0675A and mucin oligosaccharides as previously described [23], with the following modifications. Mucin oligosaccharides isolated from porcine gastric mucin (100, 200, and 400 ng hexose equivalent) were preincubated with His-BL0675A (15 µg) for 1 hr at room temperature and then added to PCM-coated wells for 1 hr. After washing three times with HBS-EP buffer (pH 7.4), the anti-His-tag antibody was added for 1 hr at room temperature, and the reaction was detected as described above.

**Preparation of cell surface proteins**

The *B. longum* subsp. *longum* strains were cultivated anaerobically in 50 ml of TOS broth at 37°C for 12 hr and then centrifuged (8,000 × g, 10 min, 4°C). Pelleted cells were suspended in 300 µl extraction buffer containing 50 mM Tris-HCl, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20; pH 7.4) at flow rate of 30 µl/min. Polyclonal anti-BL0675 A-type antibodies were raised in rabbits immunized with His-BL0675A. Twenty micrograms of protein samples were separated by SDS-PAGE in 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked with 5% (w/v) skim milk in PBS-0.05% Tween 20 (PBS-T) for 24 hr at 4°C, washed with PBS-T, and incubated with anti-BL0675 A–type polyclonal antibodies (1:1,000 in PBS-T) for 1 hr at room temperature. Membranes were then washed and incubated for 1 hr with horseradish peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich) diluted at 1:2,000 in PBS-T. After washing, the TMB Membrane Peroxidase Substrate (KPL) was added to develop the signals.

**Western blotting**

Polyclonal anti-BL0675 A-type antibodies were raised in rabbits immunized with His-BL0675A. Twenty micrograms of protein samples were separated by SDS-PAGE in 10% polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were blocked with 5% (w/v) skim milk in PBS-0.05% Tween 20 (PBS-T) for 24 hr at 4°C, washed with PBS-T, and incubated with anti-BL0675 A–type polyclonal antibodies (1:1,000 in PBS-T) for 1 hr at room temperature. Membranes were then washed and incubated for 1 hr with horseradish peroxidase-conjugated anti-rabbit IgG (Sigma-Aldrich) diluted at 1:2,000 in PBS-T. After washing, the TMB Membrane Peroxidase Substrate (KPL) was added to develop the signals.

**Bacterial adhesion assay**

Bacterial adhesion to PCMs was assessed using diagnostic glass slides as previously described [24]. Briefly, diagnostic glass slides (Matsunami Glass Ind.
Ltd., Osaka, Japan) were coated with 100 ng of PCMs (40 µl/well) for 12 hr at 4°C. After washing three times with PBS containing 0.1% (w/v) bovine serum albumin (BSA), the slides were incubated with 5% (w/v) BSA-PBS for 1 hr at room temperature. Then, 40 µl of bacterial suspensions (equivalent to OD$_{600}$ = 1.0) was added to the wells and incubated 37°C for 2 hr. The wells were washed three times with 0.1% (w/v) BSA-PBS to remove unbound bacteria and stained with methylene blue. Randomly chosen fields were photographed under an Olympus BX53 microscope (Olympus, Tokyo, Japan), and bacteria were counted in five fields.

To determine whether anti-BL0675 A-type polyclonal antibodies reduced B. longum subsp. longum binding to PCMs, BL0675 A-type antiserum and normal rabbit serum (control) diluted 1:50 were added to 40 µl of bacterial suspensions, which were then incubated for 1 hr at 37°C. The adhesion assay was performed as described above.

**Statistical analysis**

The GraphPad Prism 6 software (GraphPad Software, San Diego, CA, USA) was used to perform statistical analysis. Significant differences were determined using one-way analysis of variance (ANOVA) with a post hoc Dunnett’s test (for the bacterial adhesion test) or Tukey’s test (for the His-BL0675-binding test). The number of individual experiments (n) is indicated in the figure legends. Differences with p values less than 0.05 were considered statistically significant.

**RESULTS**

**Expression and purification of His-BL0675A**

His-BL0675A was expressed in *E. coli* Rosetta 2 and purified on HisTrap and ion exchange columns. As evidenced by protein bands detected by SDS-PAGE (Fig. 1), the molecular weights of purified His-BL0675A, B, C, D, and E were consistent with the calculated molecular masses (Table 2).

**Affinity of His-BL0675 for PCMs**

The binding of the purified His-BL0675 proteins to PCMs was determined by SPR analysis. Figure 2A shows the RUs at the start of dissociation for different His-BL0675 types at 1,000 nM. His-BL0675A showed significantly greater binding to PCMs than types B, D, and E did; however, binding of His-BL0675C to PCMs was not detected. These results demonstrate that the BL0675 types have differing affinities to PCMs. Moreover, as shown by kinetic analysis, His-BL0675A demonstrated concentration-dependent interaction in the range of 400–1,100 nM, suggesting that the binding was specific (Fig. 2B). The $K_D$ value for binding of His-BL0675A to PCMs was estimated to be $9.82 \times 10^{-8}$ M ($k_a$, $2.84 \times 10^4$ M$^{-1}$s$^{-1}$, $k_d$, $2.79 \times 10^{-3}$ s$^{-1}$). The chi-square value was 18.5, indicating that the model used

*Not including the N-terminal secretion signal sequence and the C-terminal sortase recognition site
adequately described our data. In contrast, other types of His-BL0675 (the B, C, D, and E types) did not exhibit concentration-dependent and stable sensorgrams (Fig. 2B), suggesting that the interaction was nonspecific and/or that higher binding occurred on the blank surface than the PCM-immobilized surface.

We next examined the binding of His-BL0675A to mucin carbohydrate chains by competitive ELISA. The results demonstrated that His-BL0675 binding to PCMs increased proportionally to its concentration (Fig. 3A) and was inhibited by mucin oligosaccharides in a dose-dependent manner (Fig. 3B).

**Evaluation of BL0675-mediated adhesion of B. longum subsp. longum to PCMs**

The cell surface fractions of five *B. longum* subsp. *longum* strains were analyzed for BL0675 expression by western blotting. The BL0675 A type with a molecular mass of approximately 50,000 was detected in all strains except strain 9-5, suggesting that it is expressed on the cell surface in strains 1-1, 1-7, 3-113, and 9-129 (Fig. 4A).

We next examined the effects of polyclonal anti-BL0675 A-type antibodies on the adhesion of *B. longum* subsp. *longum* strains to PCMs. As shown in Fig. 4B, adhesion of the five *B. longum* subsp. *longum* strains demonstrated good correlation with BL0675 expression levels. Treatment with BL0675 antibodies significantly reduced the adhesion of *B. longum* subsp. *longum* strains 1-1, 1-7, 3-113, and 9-129 compared with untreated control cultures. However, pretreatment with normal rabbit serum also reduced the adhesion of *B. longum* subsp. *longum* strains 3-113 and 9-129 to PCMs.

**DISCUSSION**

A previous study showed that *bl0675* ORFs encoding a putative fimbria-associated protein are highly polymorphic among *B. longum* subsp. *longum* strains isolated from human feces [19]. However, the affinity of the putative BL0675 proteins to mucosal surfaces remains largely unknown. In this study, we evaluated the binding of five BL0675 types to PCMs and found significant variations in their affinity to PCMs. His-BL0675A exhibited strong binding to PCMs ($K_D = 9.82 \times 10^{-8}$ M) that higher than the affinity of *Porphyromonas gingivalis* fimbriae to ECM proteins [25], hemoglobin, and fibrinogen [26] as determined by SPR ($K_D$ values in the micromolar range). These findings suggest that the interaction of the BL0675 A type with PCMs is relatively strong. Moreover, the binding of His-BL0675A to PCMs was dose-dependently inhibited by mucin oligosaccharides. A similar binding pattern was observed in our recent study: the binding of SpaC pilin from *Lactobacillus rhamnosus* GG was markedly reduced by addition of the mucin oligosaccharide, and the carbohydrate moieties of glycoconjugates were found to be important for this binding [27]. Our results strongly suggest that the BL0675 A type has lectin-like properties in that it binds to mucins via oligosaccharides.

Although amino acid sequence identity between the BL0675 A type and other types ranged from 41%...
to 50%, the BL0675 B, D, and E types demonstrated weak binding to PCMs, while the BL0675 C type did not show binding. These affinity patterns are similar to those observed in the five BL0675 variant types from 89 human fecal samples in our previous study in which quantitative PCR assays revealed that the A type was the most commonly distributed type (74.2% prevalence), followed by the B, D, E, and C types [19]. Host-specific adhesion is regarded as a desirable property for probiotic bacteria and is thought to be dependent more on the bacterial strain rather than on the host [28, 29]. Although it is not clear whether the distribution of bl0675 genes affects the BL0675 binding pattern, our results suggest that the BL0675 variant types significantly contribute to the adhesion of B. longum subsp. longum strains in the human GI tract. Host-specific adhesion patterns have been observed for Lactobacillus attachment to the colon. For example, the MucBD-associated domain peptide of Lactobacillus reuteri interacts with a specific colonic mucus-secreted component present in humans, rabbits, and guinea pigs, but not in mice [30], and glyceraldehyde-3-phosphate dehydrogenase of Lactobacillus plantarum recognizes blood groups A and B expressed on the nonreducing terminal sugar chains of human colonic mucin [31]. Several Bifidobacterium species are also known to exhibit differential, strain-specific binding to
carbohydrate moieties of glycolipids or mucins expressed in the GI tract [29, 32, 33]. Since we used porcine, and not human, mucins, it is possible that BL0675 types other than the A type would interact with human mucins via a more stringent carbohydrate recognition process, which we were unable to detect with porcine mucins. Further studies are needed to characterize the specific binding affinity of BL0675 types to mucin carbohydrates.

Reduction in the adhesion of B. longum subsp. longum strains to PCMs was observed when bacteria were pretreated with the BL0675 antibodies. It is likely that BL0675 is important for the establishment of GI colonization by B. longum subsp. longum strains; however, this reduction in adhesion was strain specific. Some strains were also inhibited by normal rabbit serum, suggesting that the non-BL0675-based inhibition effect of rabbit serum interferes with adhesion to PCMs through mechanisms such as steric hindrance. Pili and fimbriae are multisubunit protein polymers of high molecular weight that mediate bacterial adhesion via the tip of the polygonal structure [21, 34, 35]. Although we detected the BL0675 monomer with a calculated molecular mass of approximately 50,000, we were unable to identify high molecular weight polymers, suggesting that in B. longum subsp. longum, bl0675 ORFs encode putative fimbrial proteins, which function as adhesins without polymerization into multiglycoprotein structures such as pili. Streptococcus pneumoniae pilus-associated adhesin also binds to host cells even in the absence of polymeric pilus formation [36, 37]. On the other hand, the expression of the pilimbral subunit BL0675 by B. longum subsp. longum LMG 13197 [38] or sortase-dependent pili by B. bifidum PRL2010 [17] is influenced by the presence of complex carbohydrates in the media. Moreover, the GI niche with specific thermal, acidic, and osmotic conditions influences the expression of B. bifidum PRL2010 sortase-dependent pili, which is also enhanced by co-culture of PRL2010 with Lactobacillus paracasei [39]. Therefore, we hypothesize that the carbohydrate composition of media as well as other environmental factors may affect BL0675 expression and/or pilus polymerization.

Several Bifidobacterium strains have the ability to adhere to the GI tract, and some strains of intestinal origin express cell surface adhesion factors, including BopA [40–42], sortase-dependent pili [15], and transaldolase [43] in B. bifidum and Tad Pili in B. breve [16]. However, to date, the properties of adhesion of B. longum subsp. longum to the mucosal surface have been largely unknown. We believe that our study of the binding properties of BL0675 related to mucin adhesion will contribute to the understanding of the mechanism underlying B. longum subsp. longum attachment to and colonization of the mammalian GI tract.

**ACKNOWLEDGEMENTS**

We would like to thank Yuki Motomura (Kitasato University) for technical help. This work was supported by a Grant-in-Aid for Scientific Research C (24580397) from the Japan Society for the Promotion of Science (JSPS) and the Kitasato Research Project for Lactic Acid Bacteria.

**REFERENCES**

1. Turroni F, Foroni E, Pizzetti P, Giubellini V, Ribbera A, Merusi P, Cagnasso P, Bizzarri B, de’Angelis GL, Shanahan F, van Sinderen D, Ventura M. 2009. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol 75: 1534–1545. [Medline] [CrossRef]
2. Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, Kerr C, Hourihane J, Murray D, Fuligni F, Guemonde M, Margolles A, De Bellis G, O’Toole PW, van Sinderen D, Marchesi JR, Ventura M. 2012. Diversity of bifidobacteria within the infant gut microbiota. PLoS ONE 7: e36957. [Medline] [CrossRef]
3. Hopkins MJ, Sharp R, Macfarlane GT. 2001. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 48: 198–205. [Medline] [CrossRef]
4. Mitsuoka T. 2014. Establishment of intestinal bacteriology. Biosci MicrobIota Food Health 33: 99–116. [Medline] [CrossRef]
5. Turroni F, Ribbera A, Foroni E, van Sinderen D, Ventura M. 2008. Human gut microbiota and bifidobacteria: from composition to functionality. Antonie van Leeuwenhoek 94: 35–50. [Medline] [CrossRef]
6. Li Y, Qu X, Yang H, Kang L, Xu Y, Bai B, Song W. 2005. Bifidobacteria DNA induces murine macrophages activation in vitro. Cell Mol Immunol 2: 473–478. [Medline]
7. O’Hara AM, O’Regan P, Fanning A, O’Mahony C, Macsharry J, Lyons A, Bienenstock J, O’Mahony L, Shanahan F. 2006. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118: 202–215. [Medline] [CrossRef]
8. Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D, Motherway MO, Shanahan F, Nally K, Dougan G, van Sinderen D. 2012. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci USA 109: 2108–2113. [Medline] [CrossRef]
9. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T, Okumura R, Hara H, Yoshida H, Yamamoto M, Nomoto K, Takeda K. 2012. Probiotic *Bifidobacterium breve* induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8: e1002714. [Medline] [CrossRef]

10. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543–547. [Medline] [CrossRef]

11. Johansson MEV, Larsson JMH, Hansson GC. 2011. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of genetic analysis and morphological identification of pilus-like structures in members of the genus *Bifidobacterium*. Microb Cell Fact 10 Suppl 1: S16. [Medline] [CrossRef]

12. Hansson GC. 2012. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol 15: 57–62. [Medline] [CrossRef]

13. Katsikogianni M, Missirlis YF. 2004. Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in estimating bacteria-material interactions. Eur Cell Mater 8: 37–57. [Medline]

14. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Flynn K, Casey PG, Munoz JAM, Kearney B, Houston AM, O'Mahony C, Higgins DG, Shanahan F, Palva A, Korhonen TK, Toba T. 2002. Inhibition of the adherence of *Porphyromonas gingivalis* fimbriae and bind to different peptide motifs in salivary proteins. Infect Immun 67: 2053–2059. [Medline]

15. Turroni F, Serafini F, Foroni E, Duranti S, O’Connell Motherway M, Taverniti V, Magiﬁesta M, Milani C, Viapiani A, Roversi T, Sánchez B, Santoni A, Gioiosa L, Ferrarini A, Delledonne M, Margolles A, Piazza L, Palanza P, Bolchi A, Guglielmetti S, van Sinderen D, Ventura M. 2013. Role of sortase-dependent pili of *Bifidobacterium bifidum* PRL2010 in modulating bacterium-host interactions. Proc Natl Acad Sci USA 108: 110: 11151–11156. [Medline] [CrossRef]

16. O’Connell Motherway M, Zomer A, Leahy SC, Reunanen J, Bottacini F, Claesson MJ, O’Brien F, Flynn K, Casey PG, Munoz JAM, Kearney B, Houston AM, O’Mahony C, Higgins DG, Shanahan F, Palva A, de Vos WM, Fitzgerald GF, Ventura M, O’Toole PW, van Sinderen D. 2011. Functional genome analysis of *Bifidobacterium breve* UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. Proc Natl Acad Sci USA 108: 11217–11222. [Medline] [CrossRef]

17. Foroni E, Seraﬁni F, Amidani D, Turroni F, He F, Bottacini F, O’Connell Motherway M, Viapiani A, Zhang Z, Rivetti C, van Sinderen D, Ventura M. 2011. Genetic analysis and morphological identiﬁcation of pilus-like structures in members of the genus *Bifidobacterium*. Microb Cell Fact 10 Suppl 1: S16. [Medline] [CrossRef]

18. Schell MA, Karmirantzou M, Snel B, Vilanova D, Berger B, Pessi G, Zwahlen MC, Desiere F, Bork P, Delley M, Pridmore RD, Arigoni F. 2002. The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract. Proc Natl Acad Sci USA 99: 14422–14427. [Medline] [CrossRef]

19. Iguchi A, Umekawa N, Maegawa T, Tsuruta H, Odamaki T, Xiao JZ, Osawa R. 2011. Polymorphism and distribution of putative cell-surface adhesin-encoding ORFs among human fecal isolates of *Bifidobacterium longum* subsp. *longum*. Antonie van Leeuwenhoek 99: 457–471. [Medline] [CrossRef]

20. Li T, Johansson I, Hay DI, Strömberg N. 1999. Strains of *Actinomyces naeslundii* and *Actinomyces viscosus* exhibit structurally variant fimbrial subunit proteins and bind to different peptide motifs in salivary proteins. Infect Immun 67: 2053–2059. [Medline]

21. Mishra A, Devarajan B, Reardon ME, Dwivedi P, Krishnan V, Cisar JO, Das A, Narayana SVL, Ton-That H. 2011. Two autonomous structural modules in the fimbrial shaft adhesin FimA mediate *Actinomyces* interactions with streptococci and host cells during oral biofilm development. Mol Microbiol 81: 1205–1220. [Medline] [CrossRef]

22. Nishiyama K, Nakamata K, Ueno S, Terao A, Aryanthi NPD, Sujaya IN, Fukuda K, Urashima T, Yamamoto Y, Mukai T. 2015. Adhesion properties of *Lactobacillus rhamnosus* mucus-binding factor to mucin and extracellular matrix proteins. Biosci Biotechnol Biochem 79: 271–279. [Medline] [CrossRef]

23. Nishiyama K, Ochiai A, Tsubokawa D, Ishihara K, Yamamoto Y, Mukai T. 2013. Identiﬁcation and characterization of sulfated carbohydrate-binding protein from *Lactobacillus reuteri*. PLoS ONE 8: e83703. [Medline] [CrossRef]

24. Horie M, Ishiyama A, Fujihira-Ueki Y, Sillanpää J, Korhonen TK, Toba T. 2002. Inhibition of the adherence of *Escherichia coli* strains to basement membrane by *Lactobacillus crispatus* expressing an S-layer. J Appl Microbiol 92: 396–403. [Medline] [CrossRef]

25. Nakamura T, Amano A, Nakagawa I, Hamada S. 1999. Speciﬁc interactions between *Porphyromonas gingivalis* fimbriae and human extracellular matrix proteins. FEMS Microbiol Lett 175: 271–279. [Medline] [CrossRef]

26. Amano A, Nakamura T, Kimura S, Morisaki I, Nakagawa I, Kawabata S, Hamada S. 1999. Molecular interactions of *Porphyromonas gingivalis* fimbriae with host proteins: kinetic analyses based on surface plasmon resonance. Infect Immun 67: 2399–2405. [Medline]

27. Nishiyama K, Ueno S, Sugiyama M, Yamamoto Y, Mukai T. 2015. *Lactobacillus rhamnosus* GG SpaC pilin subunit binds to the carbohydrates moieties of intestinal glycoconjugates. Anim Sci J (Epub ahead of print). [Medline] [CrossRef]

28. Mackenzie DA, Jeffers F, Parker ML, Vibert-Vallet A, Bongaerts RJ, Roos S, Walter J, Juge N. 2010. Strain-
specific diversity of mucus-binding proteins in the adhesion and aggregation properties of *Lactobacillus reuteri*. Microbiology 156: 3368–3378. [Medline] [CrossRef]

29. Nishiyama K, Kawanabe A, Miyauchi H, Abe F, Tsubokawa D, Ishihara K, Yamamoto Y, Mukai T. 2014. Evaluation of bifidobacterial adhesion to acidic sugar chains of porcine colonic mucins. Biosci Biotechnol Biochem 78: 1444–1451. [Medline] [CrossRef]

30. Coïc YM, Baleux F, Poyraz Ö, Thibeaux R, Labruyere E, Chretien F, Sobhani I, Lazure T, Wyplosz B, Schneider G, Mulard L, Sansonetti PJ, Marteyn BS. 2012. Design of a specific colonic mucus marker using a human commensal bacterium cell surface domain. J Biol Chem 287: 15916–15922. [Medline] [CrossRef]

31. Kinoshita H, Wakahara N, Watanabe M, Kawasaki T, Matsuo H, Kawai Y, Kitazawa H, Ohnuma S, Miura K, Horii A, Saito T. 2008. Cell surface glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of *Lactobacillus plantarum* LA 318 recognizes human A and B blood group antigens. Res Microbiol 159: 685–691. [Medline] [CrossRef]

32. Mukai T, Kaneko S, Matsumoto M, Ohori H. 2004. Binding of *Bifidobacterium bifidum* and *Lactobacillus reuteri* to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int J Food Microbiol 90: 357–362. [Medline] [CrossRef]

33. Huang IN, Okawara T, Watanabe M, Kawai Y, Kitazawa H, Ohnuma S, Shibata C, Horii A, Kimura K, Taketomo N, Xiao JZ, Iwatsuki K, Saito T. 2013. New screening methods for probiotics with adhesion properties to sialic acid and sulphate residues in human colonic mucin using the Biacore assay. J Appl Microbiol 114: 854–860. [Medline] [CrossRef]

34. Mandlik A, Świerczynski A, Das A, Ton-Thät H. 2008. Pili in Gram-positive bacteria: assembly, involvement in colonization and biofilm development. Trends Microbiol 16: 33–40. [Medline] [CrossRef]

35. Kang HJ, Baker EN. 2012. Structure and assembly of Gram-positive bacterial pili: unique covalent polymers. Curr Opin Struct Biol 22: 200–207. [Medline] [CrossRef]

36. Nelson AL, Ries J, Bagnoli F, Dahlberg S, Fäldker S, Rounioja S, Tschöp J, Morfeldt E, Ferlenghi I, Hilleröd M, Holdén DW, Rappuoli R, Normark S, Barocchi MA, Henriques-Normark B. 2007. RrgA is a pilus-associated adhesin in *Streptococcus pneumoniae*. Mol Microbiol 66: 329–340. [Medline] [CrossRef]

37. Shaik MM, Maccagni A, Tourcier G, Di Guilmi AM, Dessen A. 2014. Structural basis of pilus anchoring by the ancillary pilin RrgC of *Streptococcus pneumoniae*. J Biol Chem 289: 16988–16997. [Medline] [CrossRef]

38. González R, Klaassens ES, Malinen E, de Vos WM, Vaughan EE. 2008. Differential transcriptional response of *Bifidobacterium longum* to human milk, formula milk, and galactooligosaccharide. Appl Environ Microbiol 74: 4686–4694. [Medline] [CrossRef]

39. Turroni F, Serafini F, Mangifesta M, Arioli S, Mora D, van Sinderen D, Ventura M. 2014. Expression of sortase-dependent pili of *Bifidobacterium bifidum* PRL2010 in response to environmental gut conditions. FEMS Microbiol Lett 357: 23–33. [Medline] [CrossRef]

40. Gleirser M, Grimm V, Zhurina D, Yuan J, Riedel CU. 2012. Improved adhesive properties of recombinant bifidobacteria expressing the *Bifidobacterium bifidum*-specific lipoprotein BopA. Microb Cell Fact 11: 80. [Medline] [CrossRef]

41. Guglielmetti S, Tamagnini I, Mora D, Minuzzo M, Scarafoni A, Arioli S, Hellman J, Karp M, Parini C. 2008. Implication of an outer surface lipoprotein in adhesion of *Bifidobacterium bifidum* to Caco-2 cells. Appl Environ Microbiol 74: 4695–4702. [Medline] [CrossRef]

42. Kainulainen V, Reunanen J, Hiippala K, Guglielmetti S, Vesterlund S, Palva A, Satokari R. 2013. BopA does not have a major role in the adhesion of *Bifidobacterium bifidum* to intestinal epithelial cells, extracellular matrix proteins, and mucus. Appl Environ Microbiol 79: 6989–6997. [Medline] [CrossRef]

43. González-Rodríguez I, Sánchez B, Ruiz L, Turroni F, Ventura M, Ruas-Madiedo P, Güeimonde M, Margolles A. 2012. Role of extracellular transaldolase from *Bifidobacterium bifidum* in mucin adhesion and aggregation. Appl Environ Microbiol 78: 3992–3998. [Medline] [CrossRef]